The present disclosure is generally related to relieving the side effects of cannabis.
Cannabis is a genus belonging to the family of cannabaceae. Three common species include Cannabis sativa, Cannabis indica, and Cannabis ruderalis. Cannabis has a long history being used for medicinal, therapeutic, and recreational purposes. Historical delivery methods for cannabis have involved smoking (e.g., combusting) the dried cannabis plant material. Alternative delivery methods such as ingesting typically require extracts of the cannabis biomass, such as cannabis concentrates or cannabis oils. Often, cannabis extracts are formulated using any convenient pharmacologically or food-grade acceptable diluents, carriers or excipients to produce a composition, which collectively may be known as cannabis derivative products or cannabis products. These may for example include cannabis topicals, edibles, or vaping products.
Cannabis contains a unique class of terpeno-phenolic compounds known as cannabinoids or phytocannabinoids. The principle cannabinoids present in cannabis are the delta-9-tetrahydrocannabinolic acid (THCA) and cannabidiolic acid (CBDA). The THCA does not have its own psychoactive properties as is, but may be decarboxylated to delta-9-tetrahydrocannabinol (THC), which is a potent psychoactive cannabinoid. The neutral form of CBDA is cannabidiol (CBD), which is a major cannabinoid substituent in hemp cannabis. CBD is non-psychoactive and is widely known to have therapeutic potential for a variety of medical conditions. The proportion of cannabinoids in the plant may vary from species to species, as well as vary within the same species at different times and seasons. Furthermore, the proportion of cannabinoids in a plant may further depend upon soil, climate, and harvesting time and methods. Thus, based on the proportion of the cannabinoids present in a plant variety, the psychoactive and medicinal effects obtained from different plant varieties may vary. Such variance is further exacerbated by the presence of certain terpenoid or phenolic compounds that may also have pharmacological activity.
THC and CBD have been found to have opposing neuropharmacological actions. THC is known to potentially produce psychotic-like and anxiogenic effects in humans, depending on the dose delivered. In contrast, CBD may have anti-psychotic properties, is anxiolytic, and may be neuroprotective in humans. THC is a partial agonist, whereas CBD is an antagonist at CB1 and CB2 receptors. CBD has also been suggested to inhibit the reuptake of the endogenous cannabinoid, anandamide.
However, the relative THC/CBD ratio of cannabis varies greatly. Levels of CBD can range from virtually none to up to 40%. Higher levels of THC are found in certain cultivars and in cross-bred strains, which are increasingly dominating the illicit drug market. In addition to effects on psychotic symptoms and anxiety, THC and CBD may have opposing effects in the processes involved in addiction. The reinforcing effects of THC have been repeatedly shown. Synthetic THC produces conditioned place preference in rats and decreases the threshold for intercranial self-stimulation in animal studies. CBD on its own is not acutely reinforcing in rats. However, CBD has been shown to reverse the conditioned place preference effect induced by THC in CBD to THC ratios of 1:1 and 1:10, which suggests that CBD may modulate the reinforcing effects of THC. CBD has also been suggested to have a function in the modulation of addictive behavior. Preclinical studies have shown that acute administration of CBD can enhance extinction of both cocaine and amphetamine conditioned place preference. CBD has also been found to attenuate the reinstatement of opioid seeking in rats. Given the opposing neuropharmacological actions of THC and CBD, and the capacity of CBD to modulate the acute reinforcing effects of THC in rats, it is hypothesized that CBD may also counteract some of the reinforcing effects of THC in humans.
THC has been the primary focus of cannabis research since 1964, when Raphael Mechoulam isolated and synthesized it. More recently, the synergistic contributions of CBD to cannabis pharmacology and analgesia have been scientifically demonstrated. Other phytocannabinoids (e.g., tetrahydrocannabivarin, cannabigerol and cannabichromene) exert additional effects of therapeutic interest. Innovative conventional plant breeding has yielded cannabis chemotypes expressing high titres of each component for future study. Additionally, another echelon of phytotherapeutic agents contributes to the effects of cannabis, the cannabis terpenoids and terpenes such as limonene, myrcene, α-pinene, linalool, β-caryophyllene, caryophyllene oxide, nerolidol, and phytol. Terpenoids share a precursor with phytocannabinoids and are all flavor and fragrance components common to human diets that have been designated “Generally Recognized as Safe” by the U.S. Food and Drug Administration and other regulatory agencies. Terpenoids are quite potent and can affect animal, including human, behavior when inhaled from ambient air at serum levels in the single digits ng-mL. Terpenoids display unique therapeutic effects that may contribute meaningfully to the entourage of effects of cannabis-based medicinal extracts. Particular focus may be placed on phytocannabinoid-terpenoid interactions that could produce synergy with respect to treatment of pain, inflammation, depression, anxiety, addiction, epilepsy, cancer, fungal, and bacterial infections such as methicillin-resistant Staphylococcus aureus. Scientific evidence has presented non-cannabinoid plant components as putative antidotes to intoxicating effects of THC that could increase its therapeutic index.
The general knowledge on cannabis toxicity has improved, but quantitative data are still lacking. Little is known about the somatic complications associated with cannabis exposure. Available data rest upon case reports and only a few studies have been conducted in this field. Psychiatric disorders related to cannabis exposure are somehow still controversial. Methods for utilizing the entourage effects in a composition and apparatus have been proposed. Phytocannabinoid-terpenoid synergy, if proven, increases the likelihood that an extensive pipeline of new therapeutic products is possible from this venerable plant.
There exists a need for a cannabinoid and terpenoid based treatment for the onset of side effects related to the consumption of cannabis, especially cannabis with a relatively high ratio of THC to other cannabinoids such as CBD.
The present invention is concerned with a composition and apparatus capable of providing relief from side effects and symptoms associated with the consumption of cannabis and/or its constituent compounds, namely THC. Side effects and symptoms associated with the consumption of cannabis and/or its constituent components include, for example, red eyes, poor muscle coordination, delayed reaction times, increased appetite, mood swings, anxiety, panic, hallucinations, headache, dizziness, drowsiness, nausea, and paranoia.
Embodiments of the present disclosure include systems and methods for providing cannabis side effect and symptom relief.
The cannabis remedy kit may include the user device 112 that is capable of downloading and executing the cannabis remedy application 114. The cannabis remedy application 114 may store user profile data and recommend a remedy based on type and amount of cannabis consumed and severity of symptoms. The cannabis remedy application 114 may include several software modules a user profile 116, a usage tracking 118, a remedy database 120, a side-effect monitoring 122, a recommendation algorithm, and a create remedy 126.
The user profile 116 contains the user data that may be analyzed by the recommendation algorithm 124 to determine a recommended remedy. The profile 116 may include data such as the users height, weight, age, sex, medical information, current medications, personality type (e.g., introvert or extrovert), cannabis tolerance (e.g. high, medium, or low), cannabis vehicle preferences (e.g. smoking, vaporizing, edibles and drinkables, topical treatments, etc.).
The usage tracking module 118 of the cannabis remedy application 114 may allow the user to accurately track their cannabis consumption. Based on the tracking, the recommendation algorithm module 124 may recommend a remedy for any side effects of cannabis.
The remedy database 120 is a database of remedies that the user may download from the cannabis remedy network 134. The remedy database 120 may include recommendations for specific treatment applications and specific therapeutic behaviors. Some examples of specific treatment applications are the administration of one or more cannabinoids or terpenes contained in the cannabis remedy kit 102 with a particular application device 110. Some examples of recommendations of specific therapeutic behaviors are drinking water, exercising, lying down, taking a bath, listening to relaxing music, calling a trusted friend, and seeking medical attention including telemedicine.
The side-effect monitoring module 122 cannabis remedy application 114 monitors the side-effects of cannabis of the user. Some examples of methods for side-effect monitoring 122 include tracking biometrics provided by a wearable device, tracking the users response time while performing certain tasks on the user device 112, and providing a questionnaire regarding their current experience of cannabis-related side-effects. The biometrics that the wearable device may provide include the heart rate, the heart rate variability, blood pressure, blood oxygen content, skin temperature, electroencephalograms (EEG) and electrocardiograms (ECG) activity, sleep patterns, etc. The tasks on the user device 112 may include performing a skill-based game, solving simple math problems, observing changes in scenery or sounds, etc.
The recommendation algorithm module 124 of the cannabis remedy application recommends the remedy best suited to the user based on the data from the user profile 116, usage tracking 118, and side-effect monitoring 122. In some cases, the recommendation algorithm 124 may not find a matching remedy. In such cases, the recommendation algorithm 124 requests addition remedies from the remedy network database 138 of the cannabis remedy network 134. Furthermore, the create remedy module 126 of the cannabis remedy application may allow the user to create a custom remedy, which may be uploaded to the cannabis remedy network 134 to allow other users to benefit from the created remedy.
The wearable device 128 of the cannabis remedy system 100 monitors the user's biometric data through a series of sensors. The wearable device 128 contains sensors 130 and a software module for the sensors 132. Any of several biometric sensors 130 may be used to monitor the user's biometric data such as heart rate, the heart rate variability, blood pressure, blood oxygen content, skin temperature, electroencephalograms (EEG) and electrocardiograms (ECG) activity, sleep patterns, etc. The sensor software module 132 on the wearable device 128 may be used to retrieve the sensor data from the sensors 130 of the wearable device 128 and send the sensor data to the user device 112 to monitor cannabis side-effects.
The cannabis remedy network 134 is a network in the cloud or internet, which contains and provides cannabis side-effects remedies to the cannabis remedy application 114 on the user device 112. The cannabis remedy network 134 allows users to upload cannabis remedies that were successful.
The cannabis remedy network contains a user database 136, a remedy network database 138, various remedies 140, 142, 144, and a base software 146. The user database 136 is a database of registered users of the cannabis remedy network 134 that may include each of the user's profile data. By registering with the cannabis remedy network 134, each user may download remedies from the remedy network database 138 or upload created remedies from the create remedy module 126 of the cannabis remedy application 114 to the remedy network database 138.
The remedy network database 138 is a database of remedies that a registered user may download from the cannabis remedy network. The remedies in this database 138 may include data regarding specific strains, side-effects, user attributes. The data may be used to match a user's cannabis side-effects with a recommended remedy. The remedy network data may include unlimited number of remedies 140, 142, and 144. Remedy 1 140 and remedy 2 142, and potential remedy n 144 are example remedies that will be further discussed in conjunction with
The base software 146 of the cannabis remedy network 134 may allow the user to upload and download cannabis remedies from the remedy network database 138. The base software 146 may also match user data located in the user database 136 with the best remedy for cannabis side effects based on the recommendation algorithm 124 on the user device.
The remedy database 120 is a database of remedies that the user has downloaded from the remedy network database 138 of the cannabis remedy network 134. The remedy database 120 identifies the name of the remedy, the associated side-effects, the associated cannabis products, the recommended treatments, and the recommended behavior, as seen in
The foregoing detailed description of the technology has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the technology to the precise form disclosed. Many modifications and variations are possible in light of the above teaching. The described embodiments were chosen in order to best explain the principles of the technology, its practical application, and to enable others skilled in the art to utilize the technology in various embodiments and with various modifications as are suited to the particular use contemplated. It is intended that the scope of the technology be defined by the claims.
The present patent application is a continuation of International Application No. PCT/IB2019/058925 filed Oct. 18, 2019, which claims the priority benefit of U.S. provisional patent application 62/750,146 filed Oct. 24, 2018, the disclosures of which are incorporated by reference herein.
| Number | Date | Country | |
|---|---|---|---|
| 62750146 | Oct 2018 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/IB2019/058925 | Oct 2019 | US |
| Child | 17239777 | US |